All In Biotech

Drug Trial Radar · NCT03803553

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Apr 16, 2020

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Massachusetts General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Stand Up To Cancer
First posted
Jan 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab

Conditions

  • Metastatic Colon Cancer
  • Stage III Colon Cancer

Interventions

  • FOLFIRI ProtocolDrug

    FOLFIRI cycle will be two weeks (14 days) long, with FOLFIRI administered on Days 1-3. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of FOLFIRI chemotherapy.

  • ACTIVE SURVEILLANCEOther

    Will be followed with observation and monitoring with imaging, tumor markers, and ctDNA collections

  • Nivolumab ProtocolDrug

    Nivolumab cycle will be four weeks (28 days) long, with Nivolumab administered on day 1. Participants will receive up to 12 four-week cycles (for a total of 48 weeks) of Nivolumab treatment.

  • Encorafenib/Binimetinib/Cetuximab ProtocolDrug

    Encorafenib/Binimetinib will be taken orally every day and Cetuximab will be administered intravenously on day 1 of each cycle. Cycles are 14 days long. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of Encorafenib/Binimetinib/Cetuximab.

  • Trastuzumab + PertuzumabDrug

    Trastuzumab (Herceptin) is received by intravenous administration and Pertuzumab is received intravenously by infusion on Day 1 of each cycle. Cycles are 21 days long. Participants will receive up to 8 cycles of Trastuzumab and Pertuzumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survival (DFS)Time frame: 5 years
  2. Clearance rate of ctDNATime frame: 7 Months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Weill Cornell Medical College

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.